-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From: Insight database
The fifth batch of centralized procurement quotations has come to an end.
A total of 62 drugs have been included this time.
The procurement amount on the provincial platform in 2020 will reach 55 billion yuan, a record high for centralized procurement
.
From the perspective of drug dosage forms purchased, the number of injections accounted for half, and the amount involved accounted for 70%, becoming the main dosage form of this centralized procurement
Judging from the current quotations, the price cuts of some varieties are still very large.
For example, in the bidding for docetaxel injections, 6 domestic companies won the bids, and the winning bids were Hengrui Medicine (22.
6), Zhengda Tianqing (29.
8), Yangzijiang Pharmaceutical (30), Qilu Pharmaceutical (54.
1), Huiyu Pharmaceutical (58.
4), and Osaikang Pharmaceutical (68.
94) all dropped by more than 90%, while the original research company Sanofi (860) was eliminated
.
Docetaxel injection is one of the commonly used drugs for the treatment of tumors in China, and it is listed as a large variety with sales exceeding 1 billion in China
In the bidding for paclitaxel injections, three domestic companies won the bids.
The winning bids were Yangzijiang Pharmaceutical (7.
24), Wuxi Yew Pharmaceuticals (68), and Sichuan Huiyu Pharmaceuticals (73.
8) .
The original research company Bristol-Myers Squibb (763 ) Is out
.
Public data shows that the sales of paclitaxel in domestic public medical institutions exceeded 7.
In this centralized procurement, 3 billion large varieties of oxaliplatin injection (50 mg/bottle) were selected in the bidding for 4 companies, namely Hengrui (91.
8), Qilu Pharmaceutical (198), Sichuan Huiyu (236.
8), and the original research competition.
Nofi (310.
51)
.
At present, it seems that some of the original research companies' quotations are still Buddhist, while many domestic companies have received the latest news of centralized procurement.
For example, Kelun Pharmaceutical, the main injection company, has selected all of the 11 centralized procurement products this time
.
Among the 13 varieties of Qilu Pharmaceutical, except for Decitabine and Fasudil, which were not selected, a total of 11 varieties have won the bid
.
The rate of decline has also remained at a high level, but from the perspective of the constituency's order, Qilu may not have cut the price the most this time
In addition, all 4 varieties of Sichuan Huiyu were selected, namely bendamustine hydrochloride for injection, paclitaxel injection, docetaxel injection, and oxaliplatin injection
According to public information, Hengrui's three major varieties of oxaliplatin, docetaxel, and cisatracurium benzenesulfonate injections all won the bid, and the contrast agent iodixanol was eliminated
The following are some of the company's quotations compiled by the Insight database based on public information, only for industry reference, and the official announcement shall prevail
